Characteristics of polycystic ovary syndrome throughout life

被引:94
作者
Louwers, Yvonne V. [1 ]
Laven, Joop S. E. [1 ]
机构
[1] Erasmus MC, Dept Obstet & Gynaecol, Div Reprod Endocrinol & Infertil, NL-3000 CA Rotterdam, Netherlands
来源
THERAPEUTIC ADVANCES IN REPRODUCTIVE HEALTH | 2020年 / 14卷
关键词
adolescence; amenorrhea; anovulation; cardiovascular disease; diabetes mellitus; health risks; hyperandrogenism; menopause; oligomenorrhea; polycystic ovarian morphology; polycystic ovary syndrome; IMPAIRED GLUCOSE-TOLERANCE; CARDIOVASCULAR-DISEASE; NATIONWIDE POPULATION; DIAGNOSTIC-CRITERIA; METABOLIC SYNDROME; MENSTRUAL CYCLES; RISK-FACTORS; WOMEN; PREVALENCE; PCOS;
D O I
10.1177/2633494120911038
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age. It is a complex disease in which genetic, endocrine, environmental, and behavioral factors are intertwined, giving rise to a heterogeneous phenotype with reproductive, metabolic, and psychological characteristics. Polycystic ovary syndrome affects women's health and their quality of life across the life course. During different life stages, the polycystic ovary syndrome phenotype can change, which requires a personalized diagnostic approach and treatment. Polycystic ovary syndrome is a major cause of anovulatory infertility; this disorder is also associated with hirsutism and acne. Diagnosing polycystic ovary syndrome during adolescence is challenging because the polycystic ovary syndrome criteria include normal physiological events that occur during puberty. With increasing age, the syndrome evolves from a reproductive disease to a more metabolic disorder. Along with metabolic disturbances, including insulin resistance and abnormalities of energy expenditure, polycystic ovary syndrome is recognized as a major risk factor for the development of type 2 diabetes and cardiovascular disease in later life. Moreover, there is evidence for familial clustering of endocrine and metabolic features of polycystic ovary syndrome. Environmental factors such as diet and obesity appear to contribute to the phenotype. Treatment should be tailored to the specific concerns and needs of the individual patient and involves restoring fertility, treatment of the metabolic complaints, treatment of androgen excess, and providing endometrial protection. The complexity of the disorder, and the impact on quality of life, requires a timely diagnosis, screening for complications, and management strategies for the long-term health issues associated with polycystic ovary syndrome. The syndrome remains underdiagnosed, and women experience significant delays to diagnosis.
引用
收藏
页数:9
相关论文
共 69 条
  • [1] Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: Consequences for adult reproduction
    Apter, D
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (02) : 58 - 61
  • [2] Androgen excess in women: Experience with over 1000 consecutive patients
    Azziz, R
    Sanchez, LA
    Knochenhauer, ES
    Moran, C
    Lazenby, J
    Stephens, KC
    Taylor, K
    Boots, LR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) : 453 - 462
  • [3] Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span
    Azziz, R
    Marin, C
    Hoq, L
    Badamgarav, E
    Song, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (08) : 4650 - 4658
  • [4] Polycystic ovary syndrome
    Azziz, Ricardo
    Carmina, Enrico
    Chen, ZiJiang
    Dunaif, Andrea
    Laven, Joop S. E.
    Legro, Richard S.
    Lizneva, Daria
    Natterson-Horowtiz, Barbara
    Teede, Helena J.
    Yildiz, Bulent O.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2016, 2
  • [5] Obesity and polycystic ovary syndrome
    Barber, T. M.
    McCarthy, M. I.
    Wass, J. A. H.
    Franks, S.
    [J]. CLINICAL ENDOCRINOLOGY, 2006, 65 (02) : 137 - 145
  • [6] Longterm management of Polycystic Ovarian Syndrome (PCOS)
    Bates, Gordon W.
    Legro, Richard S.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 373 (1-2) : 91 - 97
  • [7] The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis
    Behboudi-Gandevani, Samira
    Amiri, Mina
    Yarandi, Razieh Bidhendi
    Noroozzadeh, Mahsa
    Farahmand, Maryam
    Dovom, Marzieh Rostami
    Tehrani, Fahimeh Ramezani
    [J]. CLINICAL ENDOCRINOLOGY, 2018, 88 (02) : 169 - 184
  • [8] A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
    Boomsma, C. M.
    Eijkemans, M. J. C.
    Hughes, E. G.
    Visser, G. H. A.
    Fauser, B. C. J. M.
    Macklon, N. S.
    [J]. HUMAN REPRODUCTION UPDATE, 2006, 12 (06) : 673 - 683
  • [9] Basic infertility including polycystic ovary syndrome
    Brassard, Maryse
    AinMelk, Youssef
    Baillargeon, Jean-Patrice
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2008, 92 (05) : 1163 - +
  • [10] The phenotype of polycystic ovary syndrome ameliorates with aging
    Brown, Zoe A.
    Louwers, Yvonne V.
    Fong, Sharon Lie
    Valkenburg, Olivier
    Birnie, Erwin
    de Jong, Frank H.
    Fauser, Bart C. J. M.
    Laven, Joop S. E.
    [J]. FERTILITY AND STERILITY, 2011, 96 (05) : 1259 - 1265